Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-03-22
2011-03-22
Kelly, Robert M (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023500, C536S023100, C435S320100, C424S093100
Reexamination Certificate
active
07910564
ABSTRACT:
The present invention relates to the IL-12p40 subunit mutant gene which can produce IL-12 (interleukin 12) of human and mouse origin with high activity, the expression vector including above mutant gene and the use of them to DNA vaccine adjuvant. Particularly, it relates to IL-12p40 mutant gene which inhibits the secretion of IL-12p40 but normally secretes active IL- 12p70 by making mutation at Asn-222 (human) or Asn- 220 (mouse) amino acid of IL-12p40, which acts as a competitive inhibitor of active form of IL-12, IL-12p70. Therefore, the IL-12p40 mutant gene of the present invention can be useful for DNA vaccination and gene therapy against various diseases, for example, AIDS, hepatitis C or hepatitis B, cancer, influenza, tuberculosis and malaria, which essentially require cellular immune responses for their therapy.
REFERENCES:
patent: 6013268 (2000-01-01), Reed
patent: 818534 (1998-01-01), None
Ha, et al. (2002) Nature Biotechnology, 20: 381-86.
Aller H J. et al., N. Engl. J. Med.,321:1494-1500, 1989.
Boyer J et al., Aids, Therapeutic immunization of HIV-infected chimpanzees using HIV-1 plasmid antigens and interleukin-12 expressing plasmids ,14—1515-1522,2000.
Carra, G. et al., J. Immunol., 164 4752-4761, 2000.
Chehimi, J. et al., J Exp. Med., 179:1361-1366, 1994.
Chen, L. et al., J. Immunol ,159:351-359, 1997.
Cho et al., Vaccine, 17 1136-1144, 1999.
Choo Q L. et al., Proc Natl. Acad. Sci. USA, 91:1294-1298, 1994.
Cohen, J.,Science, 270:908, 1995.
D'Andrea et al., J. Exp. Med., 176:1387-1398,1992.
de Jong, R. et al., Science, 280:1435-1438, 1998.
Decken K et al. “Interleukin-12 is essential for a protective Th 1 response in mice infected withCryptococcus neoformans.”, Infect Immun., Oct. 1998, vol. 66(1O), pp. 4994-5000.
Fuss, I. J. et al., Gastroenterology , 117:1078-1088, 1999.
Gearing, D. P., and Cosman, D.,Cell, 66:9-10, 1991.
Geissler M. et al., J. Immunol., 159:5107-5113, 1997.
Gillessen S et al: “Mouse Interleukin-12 (IL-12) P40 Homodinner: A Potent IL-12 Antagonist” European Journal of Immunology, Weinheim,DE,vol. 25, Jan. 1995, pp. 200-205.
Ha Sang J et al; “Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization.” Nature Biotechnology. APR 2002, vol. 20, No. 4, Apr. 2002, pp. 381-386, XP002338248.
Haraguchi M—BiochemJ—312—273—1995.
Heinzel, F. P. et al.,Infect. Immun., 62:4244-4249, 1994.
Hsieh, C. S., et al., Science, 260:547-549, 1993.
Irwin M. J. et al., J. Virol., 68:5306-5044, 1994.
Iwasaki A. et al., J. Immunol., 158:4591-4601, 1997.
Kato, K. et al., Proc. Natl. Acad. Sci., 93:9085-9089, 1996.
Kuzushima,K. et al., Blood, 94:3094-3100, 1999.
Lasartte J. J. et al., J. Immunol., 162: 5270-5277, 1999.
Lee S. W. et al., J. Virol ., 72:8430-8436, 1997.
Lee Y-L et al: “Construction of Vectors Expressing Bioactive Heterodimeric and Single-Chain Murine Interleukin-12 for Gene Therapy” Human Gene Therapy, vol. 9, No. 4, Mar. 1, 1998,pp. 457-465.
Lieschke, G. J et al., Nat. Biotechnol., 15:35-40, 1997.
Lingp et al.: “Human IL-12 p40 homodimer binds to the IL-12 receptor but does not medi ate bi 01 ogi c activity,” Journal of Immunology (Baltimore, MD 1950) Jan. 1, 1995, vo1. 154, No. 1, Jan. 1, 1995, pp. 116-127.
Lotze, M T et al , Ann N.Y. Acad Sci., 795:440-454, 1996.
Marth, T. et al., J. Immunol. 162:7233-7240, 1999.
Mattner, F. et al., Eur. J. Immunol., 23:2202-2208, 1993.
Mbawuike, I N. et al., J. Infect. Dis. ,180:1477-1486, 1999.
Michel M. L. et al., Proc. Natl. Acad. Sci. USA, 92:5307-5311, 1995.
Mortarini, R. et al., C ancer Res. , 60 3559-3568, 2000.
Picotti, J. R. et al., J. Immunol., 157:1951-1957, 1996.
Podlasky, F. J. et al., Arch. Biochem. Biophys ., 294:230-237, 1992.
Rakhmilevich, A. L. et al., Proc. Natl Acad Sci USA, 93:6291-6296, 1996.
Rinaldo C. et al., J. Virol., 69:5838-5842, 1995.
Robertson, M. J., and J. Ritz., Oncologist, 1:88-97 1999.
Sang J H et al., “A Novel Function of IL-12p40 as a Chemotactic Molecule for Macrophages”, The Journal of Immunology. 1999. vo1. 163. pp. 2902-2908.
Schoenhaul D S et al , J. Immunol , 148:3433-3440, 1999.
Sin J I et al: “IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ Tcell-mediated protective immunity against herpes simplex virus-2 challenge.” 162, 2912-2921, 1999.
Tahara, H. et al., J. Immunol., 154:6466-6474, 1995.
Tedeschi V. et al., Hepatology, 25:459-462, 1997.
Trinchieri, G., Annu. Rev. Immunol., 13:251-276, 1995.
Ulmer J. B. et al., Science, 259:1745-1749, 1993.
Weiland E. et al. J. Virol., 66:3677-3682, 1992.
Yoon, C et al., EMBO J., 19:3530-3534, 2000.
Zhang, X et al., Immunity 8:591-599, 1998.
Chang Jun
Ha Sang Jun
Lee Sung Hee
Song Man Ki
Sung Young Chul
Genexine Co. Ltd.
JHK Law
Kelly Robert M
Kim Joseph H.
LandOfFree
Genes of IL-12P40 subunit mutated for improving the activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genes of IL-12P40 subunit mutated for improving the activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genes of IL-12P40 subunit mutated for improving the activity... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2676286